Centaur launches chronic heart failure generic drug in United States – Healthcare News

Centaur launches chronic heart failure generic drug in United States – Healthcare News

Centaur Pharmaceuticals Pvt Ltd. on Thursday announced the launch of a generic version of chronic heart failure drug Corlanor in the United States.

According to company’s statement, Centaur received 180-day exclusivity on generic Ivabradine hydrochloride. The Mumbai-based company, through its marketing partner Ingenus Pharmaceuticals, launched Corlanor in a dosage of 5mg and 7.5mg tablets in the US.

The US Food and Drug Administration lists ivabradine hydrochloride as a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated:

US FDA red-flags desi Viagra! Indian pharmas' erectile dysfunction drug in question over 'fake' data

US’ Biosecure Act targets China, seen to double India’s pharma contract manufacturing in 3 years

Sanofi resets footprint in India, Hyd GCC to add new digital competencies

Sanofi resets footprint in India, Hyd GCC to add new digital competencies

Pigeon droppings, lung diseases, pigeon excreta, zoonotic diseases, healthcare news,

Beware of pigeon droppings! It can permanently damage your lungs; here’s how

HIV, HIV in Tripura, HIV cases in Tripura, HIV in students, healthcare news,

Over 800 students in Tripura infected with HIV? Health Ministry dismisses claims as “misleading”

  • To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.
  • For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages six months and older.

“Ivabradine launch presents an opportunity for Centaur to expand share in the chronic heart failure drug market in the US,” said S.D Sawant, Chairman and Managing Director, Centaur Pharmaceuticals. “The company will maintain international focus and keep exploring strategic alliances and in-licensing of molecules to boost its growth.”

Centaur Pharmaceuticals ranks among India’s few, fully integrated pharmaceutical firms with proficiencies across the pharmaceutical value chain, it claimed. Centaur leverages its synergies across active pharma ingredients, R&D, contract research and manufacturing, clinical research and formulations, it stated.

Centaur generates 42% of its revenue from the international market though exports to 96 companies, the company said in a statement.

“Centaur successfully co-developed a globally patented new chemical entity, DPOCL (Trade name: WOXHEAL), for treating diabetic foot ulcer, an unmet medical need. Centaur’s clinical research division, Lifesan, collaborated with a German biotechnology company and successfully conducted Phase II and III studies in India. Centaur is awaiting marketing approval to introduce the NCE for the first time,” it stated.


link

Leave a Reply

Your email address will not be published. Required fields are marked *